Literature DB >> 10716686

Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis.

R Jalan1, N Turjanski, S D Taylor-Robinson, M J Koepp, M P Richardson, J A Wilson, J D Bell, D J Brooks.   

Abstract

BACKGROUND/AIMS: To measure cerebral benzodiazepine receptor binding using (11)C-flumazenil positron emission tomography in patients with stable chronic hepatic encephalopathy, who were also characterised by proton magnetic resonance spectroscopy.
METHODS: Six abstinent patients of mean age 61 years with alcohol related cirrhosis and grade I-II hepatic encephalopathy and 11 matched healthy volunteers were studied. Each patient's encephalopathy was defined according to clinical, psychometric, electroencephalographic, and magnetic resonance spectroscopy criteria. Using positron emission tomography, the brain volume of distribution of (11)C-flumazenil was obtained; this reflects benzodiazepine receptor availability. Proton magnetic resonance spectra were acquired at 1.5 T using a multivoxel technique; peak area ratios were calculated for choline, glutamine/glutamate, N-acetylaspartate, and creatine resonances.
RESULTS: The mean volume of distribution of (11)C-flumazenil was significantly higher in the cortex, cerebellum, and the basal ganglia in the patients compared with controls (p<0.001). In the patient group, the mean glutamine/glutamate to creatine ratio was significantly increased and the mean choline to creatine ratio was significantly decreased in all brain areas, compared with healthy volunteers. However, the N-acetylaspartate to creatine ratio was unchanged compared with controls.
CONCLUSIONS: The spectroscopy results reflect the cerebral metabolic derangement associated with hepatic encephalopathy. Stable grade I-II chronic hepatic encephalopathy in alcohol related cirrhosis may be associated with increased cerebral benzodiazepine receptor availability. However, a direct effect of previous chronic exposure to alcohol cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716686      PMCID: PMC1727897          DOI: 10.1136/gut.46.4.546

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

Review 1.  Newer approaches to therapy of hepatic encephalopathy.

Authors:  P Ferenci; A Herneth; P Steindl
Journal:  Semin Liver Dis       Date:  1996-08       Impact factor: 6.115

Review 2.  Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy?

Authors:  B D Ross; E R Danielsen; S Blüml
Journal:  Dig Dis       Date:  1996       Impact factor: 2.404

3.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

4.  Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle.

Authors:  N A Lassen; P A Bartenstein; A A Lammertsma; M C Prevett; D R Turton; S K Luthra; S Osman; P M Bloomfield; T Jones; P N Patsalos
Journal:  J Cereb Blood Flow Metab       Date:  1995-01       Impact factor: 6.200

Review 5.  Neuropharmacologic modulation of hepatic encephalopathy: experimental and clinical data.

Authors:  P Ferenci; A Herneth; A Püspök; P Steindl
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

6.  Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.

Authors:  H O Conn; C M Leevy; Z R Vlahcevic; J B Rodgers; W C Maddrey; L Seeff; L L Levy
Journal:  Gastroenterology       Date:  1977-04       Impact factor: 22.682

7.  MR imaging and spectroscopy of the basal ganglia in chronic liver disease: correlation of T1-weighted contrast measurements with abnormalities in proton and phosphorus-31 MR spectra.

Authors:  S D Taylor-Robinson; J Sargentoni; A Oatridge; D J Bryant; J V Hajnal; C D Marcus; J P Seery; H J Hodgson; N M deSouza
Journal:  Metab Brain Dis       Date:  1996-09       Impact factor: 3.584

8.  Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy.

Authors:  S D Taylor-Robinson; J Sargentoni; C D Marcus; M Y Morgan; D J Bryant
Journal:  Metab Brain Dis       Date:  1994-12       Impact factor: 3.584

9.  Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities.

Authors:  B D Ross; S Jacobson; F Villamil; J Korula; R Kreis; T Ernst; T Shonk; R A Moats
Journal:  Radiology       Date:  1994-11       Impact factor: 11.105

10.  Cerebral proton and phosphorus-31 magnetic resonance spectroscopy in patients with subclinical hepatic encephalopathy.

Authors:  S D Taylor-Robinson; C Buckley; K K Changani; H J Hodgson; J D Bell
Journal:  Liver       Date:  1999-10
View more
  15 in total

Review 1.  Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management.

Authors:  T Gerber; H Schomerus
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 2.  Neurotransmitter dysfunction in hepatic encephalopathy: new approaches and new findings.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

Review 3.  Positron emission tomography in the study of hepatic encephalopathy.

Authors:  Alan H Lockwood
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 4.  Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity.

Authors:  Scott J Moeller; Edythe D London; Georg Northoff
Journal:  Neurosci Biobehav Rev       Date:  2015-12-01       Impact factor: 8.989

5.  The cognitive profile of depressed patients with cirrhosis.

Authors:  Charmaine A Stewart; Felicity T B Enders; Mary M Mitchell; Donna Felmlee-Devine; Glenn E Smith
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 6.  Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.

Authors:  Li Huang; Matthew A Quinn; Gabriel A Frampton; Lessie Eric Golden; Sharon DeMorrow
Journal:  Dig Liver Dis       Date:  2010-10-08       Impact factor: 4.088

7.  Quantification of glutamate and glutamine using constant-time point-resolved spectroscopy at 3 T.

Authors:  Meng Gu; Natalie M Zahr; Daniel M Spielman; Edith V Sullivan; Adolf Pfefferbaum; Dirk Mayer
Journal:  NMR Biomed       Date:  2012-07-04       Impact factor: 4.044

Review 8.  Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy.

Authors:  V-P Bob Grover; M-Alex Dresner; Daniel-M Forton; Serena Counsell; David-J Larkman; Nayna Patel; Howard-C Thomas; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

Review 9.  The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy.

Authors:  Samir Ahboucha; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 10.  Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy.

Authors:  M Baraldi; R Avallone; L Corsi; I Venturini; C Baraldi; M L Zeneroli
Journal:  Metab Brain Dis       Date:  2008-12-11       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.